ClariVest Asset Management’s Myriad Genetics MYGN Stock Holding History

ClariVest Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-85,180	Closed	-$2.37M	–	715
2019 Q2	$2.37M	Sell	85,180 -600	-0.7%	-$16.9K	0.05%	233
2019 Q1	$2.85M	Sell	85,780 -4,194	-5%	-$128K	0.06%	267
2018 Q4	$2.62M	Buy	89,974 +23,687	+36%	+$852K	0.06%	258
2018 Q3	$3.05M	Buy	66,287 +27,176	+69%	+$1.21M	0.05%	253
2018 Q2	$1.46M	Buy	39,111 +39,092	+205,747%	+$1.32M	0.03%	385
2018 Q1	$1K	Hold	19	–	–	﹤0.01%	691
2017 Q4	$1K	Buy	+19	New	+$641	﹤0.01%	676
2015 Q1	–	Sell	-17,585	Closed	-$599K	–	629
2014 Q4	$599K	Sell	17,585 -135	-0.8%	-$4.79K	0.02%	267
2014 Q3	$683K	Sell	17,720 -16	-0.1%	-$597	0.03%	254
2014 Q2	$690K	Buy	+17,736	New	+$660K	0.03%	260
2013 Q4	–	Sell	-76,476	Closed	-$1.8M	–	632
2013 Q3	$1.8M	Sell	76,476 -40,984	-35%	-$1.16M	0.08%	172
2013 Q2	$3.16M	Buy	+117,460	New	+$3.4M	0.14%	144

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ClariVest Asset Management's MYGN Position: Q3 2019 in Review

ClariVest Asset Management sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 85,180 shares — an estimated $2.37M sold.

ClariVest Asset Management first reported a position in MYGN in Q2 2013 and held it in 12 quarters. The position peaked at $3.16M in Q2 2013. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

ClariVest Asset Management reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
ClariVest Asset Management sold 85,180 Myriad Genetics shares in Q3 2019, an estimated $2.37M.
ClariVest Asset Management first reported a position in Myriad Genetics in Q2 2013 and held it in 12 quarters.
ClariVest Asset Management's Myriad Genetics position peaked at $3.16M in Q2 2013.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on ClariVest Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.